Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Allschwil, Switzerland, June 05, 2025
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year.
David Veitch, Basilea's Chief Executive Officer, stated: 'This milestone payment for the Asia Pacific region, including China, reflects the strong and growing global demand for novel antifungal therapies. Continued growth of Cresemba, particularly in China, where uptake has been especially robust, reinforces its significant clinical value for patients facing life-threatening infections. We congratulate our partner Pfizer for their ongoing commitment to making Cresemba available to patients in need.'
The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region.
Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between January and December 2024 amounted to USD 562 million, a 19 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1
About Cresemba® (isavuconazole)
Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland
Phone
+41 61 606 1102
E-mail
media_relations@basilea.cominvestor_relations@basilea.com
This press release can be downloaded from www.basilea.com.
References
IQVIA Analytics Link, December 2024. In-market sales reported as moving annual total (MAT) in US dollar.
European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: June 04, 2025]
Summary of Product Characteristics (SmPC) Cresemba: https://www.medicines.org.uk/emc/search?q=cresemba [Accessed: June 04, 2025]
Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: June 04, 2025]
The registration status and approved indications may vary from country to country.
Attachment
Press release (PDF)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 minutes ago
- Business Upturn
The Enterprise World Honors Danielle Gronich as a Leading Entrepreneur in Wellness for 2025
By GlobeNewswire Published on June 6, 2025, 18:00 IST San Diego, June 06, 2025 (GLOBE NEWSWIRE) — Danielle Gronich, widely known as The Acne Guru® and CEO of CLEARSTEM Skincare, has been featured in The Enterprise World as part of its prestigious annual issue: ' The Most Impressive Entrepreneurs Leading the Wellness Industry in 2025 .' This special edition celebrates visionary leaders who are driving innovation, transforming health and beauty standards, and redefining what wellness means in today's world. Recognized for her breakthrough contributions to skincare science and holistic acne treatment, Gronich stands among a select group of trailblazers shaping the future of the wellness industry. Who is Danielle Gronich ? Danielle Gronich is a licensed clinical esthetician, researcher, and founder of the San Diego Acne Clinic. Known as The Acne Guru®, she is the Co-Founder and CEO of CLEARSTEM Skincare, a brand that merges clean beauty with clinical results. Her work is revolutionizing the way we understand acne, aging, and internal wellness. What Readers will Gain from this Story? In this cover story readers will discover how Danielle Gronich's real-world journey—from battling cystic acne to co-founding CLEARSTEM—proves that success is less about having a flawless plan and more about taking bold, intentional steps toward solving real problems. This story offers valuable takeaways for: Aspiring entrepreneurs , showing that impactful businesses often start with a simple idea and grow through listening, learning, and adapting. , showing that impactful businesses often start with a simple idea and grow through listening, learning, and adapting. Wellness-conscious consumers , who will learn how CLEARSTEM blends clinical research with holistic health to deliver clean, effective acne and anti-aging solutions. , who will learn how CLEARSTEM blends clinical research with holistic health to deliver clean, effective acne and anti-aging solutions. Skincare professionals and enthusiasts , gaining insight into the science-backed innovation behind products like the MINDBODYSKIN supplement and CELLRENEW serum. , gaining insight into the science-backed innovation behind products like the supplement and serum. Anyone struggling with acne, finding hope in CLEARSTEM's unique approach that treats skin from the inside out, backed by education, lab testing, and expert formulation. Above all, the piece emphasizes a powerful message: You don't need the perfect plan to make a difference—you just need to start. About The Enterprise World The Enterprise World is a business magazine that serves as a platform for prominent business leaders to share their journeys to success, including the challenges and breakthroughs that shaped their paths to becoming industry stars. Attachments CLEARSTEM Skincare Danielle Gronich – The Acne Guru® The Enterprise World The Most Impressive Entrepreneur Leading the Wellness Industry in 2025 | The Enterprise World Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
41 minutes ago
- Yahoo
Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?
We recently published a list of In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against other stocks that Jim Cramer discusses. In an older segment, a long-time listener asked about Bristol-Myers Squibb Co. (NYSE:BMY) given its dividend and drug pipeline. Cramer wasn't optimistic and said he'd prefer Pfizer for yield-focused investors. He stated: 'I think that you're going to be paid to wait for things… but it's going to be a long wait. If I want to be paid to wait, I'd rather be in Pfizer than I would be in Bristol-Myers.' Cramer picked the wrong name, as BMY rose +15.13% while Pfizer lagged. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company focused on developing drugs for cancer, cardiovascular disease, and immunological disorders. Although Cramer holds the stock in his charitable trust, he's still waiting for it to bottom before buying back into it. Here are his comments from May 14: 'Let's get started with the stocks that sold off hard today, because I think it's really important, because you know most, if not all, of these companies. Why don't we start with Bristol Myers, which we own for the Charitable Trust? Now here's a drug company with a decent oncology franchise that happens to be facing what's known as a huge patent cliff, alright… meaning it's about to have some highly lucrative drugs lose their patent protection, therefore not make them much money at all. We own it in part because of the yield. They're paying you to wait for new drugs that turn things around. The chief one is COBENFY. It's a potentially revolutionary drug that treats some tough neurological problems, including schizophrenia. Now we sold some of this stock when it had this ridiculous spike right here… some bizarre rotation into safety, but now Bristol's in the mid-40s. Now, we haven't bought back all of the stock that we sold. We're waiting for it to bottom because its most recent studies using COBENFY, it's one study, it came up snake eyes. Management has said over and over again that it can pay the dividend, which gives you a 5.6% yield. Why not buy more? Honestly, because I think it can go lower still without evidence that COBENFY is doing better.' A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Overall, BMY ranks 7th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at .
Yahoo
41 minutes ago
- Yahoo
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass., June 06, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
